Filing Analysis
Delisting Notice
Filed Apr 09, 2026
HIGH
Kyntra Bio, Inc. received a deficiency notice from Nasdaq on April 2, 2026, for failing to meet the $50 million total assets and revenue requirement for continued listing on the Nasdaq Global Select Market. The company also confirmed it does not meet alternative listing standards regarding shareholders' equity or market value of listed securities.
Red Flags
- Failure to meet multiple alternative listing standards (equity and market value) simultaneously.
- Significant revenue impact from assets held for sale/discontinued operations in consecutive years (2024-2025).
- Potential for delisting if a compliance plan is not accepted or executed.
Key Facts
- Received Nasdaq notification on April 2, 2026, regarding non-compliance with Listing Rule 5450(b)(3)(A).
- Non-compliance resulted from FibroGen International revenue being classified as held for sale/discontinued operations in 2024 and 2025.
- The company currently fails alternative requirements for shareholders' equity and market value of listed securities.
- Kyntra Bio has 45 days (until May 18, 2026) to submit a compliance plan to Nasdaq.
- If the plan is accepted, an extension of up to 180 days (until September 29, 2026) may be granted.
- The company is considering a transfer to the Nasdaq Capital Market as a potential remedy.
Other SEC Filing
Filed Mar 16, 2026
LOW
Kyntra Bio, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as Exhibit 99.1 to the filing.
Key Facts
- Financial results reported for the quarter and year ended December 31, 2025
- Filing date and report date of March 16, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Signed by David DeLucia, Senior Vice President and Chief Financial Officer
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.